DE60031127T2
(en)
*
|
1999-08-12 |
2007-02-01 |
Wyeth Holdings Corp. |
NSAID AND EGFR KINASE INHIBITORS PHARMACEUTICAL FORMULATION FOR THE TREATMENT OR INHIBITION OF THICK DARMPOLYPES AND COLORECTAL CANCER
|
US6432979B1
(en)
|
1999-08-12 |
2002-08-13 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps and colorectal cancer
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
JP4724657B2
(en)
|
2003-05-30 |
2011-07-13 |
アストラゼネカ ユーケー リミテッド |
process
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
ME01267B
(en)
|
2004-05-06 |
2013-06-20 |
Warner Lambert Co |
4-phenylamino-quinazolin-6-yl-amides
|
EP1838712B8
(en)
|
2004-12-14 |
2011-10-12 |
AstraZeneca AB |
Pyrazolopyrimidine compounds as antitumor agents
|
WO2006071079A1
(en)
*
|
2004-12-29 |
2006-07-06 |
Hanmi Pharm. Co., Ltd. |
Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof
|
US7820683B2
(en)
|
2005-09-20 |
2010-10-26 |
Astrazeneca Ab |
4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer
|
EP2061906B1
(en)
|
2006-09-12 |
2011-08-31 |
Genentech, Inc. |
Methods and compositions for the diagnosis and treatment of lung cancer using pdgfra, kit or kdr gene as genetic marker
|
EP1921070A1
(en)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation
|
EA200901041A1
(en)
|
2007-02-06 |
2010-02-26 |
Бёрингер Ингельхайм Интернациональ Гмбх |
BICYCLIC HETEROCYCLES CONTAINING THESE COMPOUNDS MEDICINES, THEIR APPLICATION AND METHOD OF OBTAINING THEM
|
WO2009092052A2
(en)
|
2008-01-18 |
2009-07-23 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for treating polyps
|
TWI472339B
(en)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
|
MX2010008621A
(en)
|
2008-02-07 |
2010-09-24 |
Boehringer Ingelheim Int |
Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production.
|
JP5739802B2
(en)
|
2008-05-13 |
2015-06-24 |
アストラゼネカ アクチボラグ |
4- (3-Chloro-2-fluoroanilino) -7-methoxy-6-{[1- (N-methylcarbamoylmethyl) piperidin-4-yl] oxy} quinazoline fumarate
|
US8426430B2
(en)
*
|
2008-06-30 |
2013-04-23 |
Hutchison Medipharma Enterprises Limited |
Quinazoline derivatives
|
CA2733153C
(en)
|
2008-08-08 |
2016-11-08 |
Boehringer Ingelheim International Gmbh |
Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
|
SG10201402742YA
(en)
|
2009-03-20 |
2014-08-28 |
Genentech Inc |
Bispecific anti-her antibodies
|
RU2012124093A
(en)
|
2009-11-12 |
2013-12-20 |
Дженентек, Инк. |
METHOD FOR INCREASING DENSITY OF DENDRITIC SPIKES
|
AR079984A1
(en)
|
2010-01-12 |
2012-03-07 |
Hoffmann La Roche |
TRICYCLIC HETEROCICLIC COMPOUNDS, COMPOSITIONS AND ITS USE IN THE TREATMENT OF DISEASES MEDIATED BY THE INHIBITION OF JAK1
|
RU2587619C2
(en)
|
2010-02-18 |
2016-06-20 |
Дженентек, Инк. |
Neuregulin antagonists and use thereof in treating malignant growth
|
BR112012023382A2
(en)
|
2010-03-17 |
2018-05-15 |
F Hoffmann La Roche Ag T |
imidazopyridine compounds, compositions and methods of use.
|
RU2012148699A
(en)
|
2010-04-16 |
2014-05-27 |
Дженентек, Инк. |
FOXO3A AS A PROGNOSTIC BIOMARKER FOR PI3K / ACT KINASE PATH INHIBITOR EFFICIENCY
|
CA2808236A1
(en)
|
2010-08-31 |
2012-03-08 |
Genentech, Inc. |
Biomarkers and methods of treatment
|
MX2013003019A
(en)
|
2010-09-15 |
2013-05-28 |
Hoffmann La Roche |
Azabenzothiazole compounds, compositions and methods of use.
|
CA2817785A1
(en)
|
2010-11-19 |
2012-05-24 |
Toby Blench |
Pyrazolopyridines and pyrazolopyridines and their use as tyk2 inhibitors
|
WO2012085176A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
|
WO2013007765A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Fused tricyclic compounds for use as inhibitors of janus kinases
|
WO2013007768A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
|
WO2013024011A1
(en)
|
2011-08-12 |
2013-02-21 |
F. Hoffmann-La Roche Ag |
Indazole compounds, compositions and methods of use
|
BR112014003431A2
(en)
|
2011-08-17 |
2017-06-13 |
Genentech Inc |
antibody, nucleic acid, host cell, method of producing an antibody, immunoconjugate, pharmaceutical formulation, pharmaceutical agent, use of the antibody, method of treating an individual who has cancer, and time-lapse method for tumor recurrence
|
CN103827115A
(en)
|
2011-09-20 |
2014-05-28 |
弗·哈夫曼-拉罗切有限公司 |
Imidazopyridine compounds, compositions and methods of use
|
JP2015500638A
(en)
|
2011-11-30 |
2015-01-08 |
ジェネンテック, インコーポレイテッド |
ERBB3 mutations in cancer
|
BR112014024017A8
(en)
|
2012-03-27 |
2017-07-25 |
Genentech Inc |
METHODS FOR TREATMENT OF A TYPE OF CANCER, FOR TREATMENT OF CARCINOMA, FOR SELECTING A THERAPY AND FOR QUANTIFICATION AND HER3 INHIBITORS
|
MX2015010791A
(en)
|
2013-02-22 |
2015-11-26 |
Hoffmann La Roche |
Methods of treating cancer and preventing drug resistance.
|
US9925240B2
(en)
|
2013-03-06 |
2018-03-27 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
RU2015143517A
(en)
|
2013-03-13 |
2017-04-19 |
Дженентек, Инк. |
Pyrazole-containing compounds and their use
|
RU2015139054A
(en)
|
2013-03-14 |
2017-04-19 |
Дженентек, Инк. |
METHODS FOR TREATING CANCER AND PREVENTION OF DRUG RESISTANCE OF CANCER
|
EP2968540A2
(en)
|
2013-03-14 |
2016-01-20 |
Genentech, Inc. |
Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
|
CA2905123A1
(en)
|
2013-03-15 |
2014-09-18 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
RU2016112568A
(en)
|
2013-09-05 |
2017-10-06 |
Дженентек, Инк. |
ANTIPROLIFERATIVE COMPOUNDS
|
WO2015049325A1
(en)
|
2013-10-03 |
2015-04-09 |
F. Hoffmann-La Roche Ag |
Therapeutic inhibitors of cdk8 and uses thereof
|
WO2015058132A2
(en)
|
2013-10-18 |
2015-04-23 |
Genentech, Inc. |
Anti-rspo antibodies and methods of use
|
HUE047699T2
(en)
|
2013-12-17 |
2020-05-28 |
Hoffmann La Roche |
Methods of treating cancers using pd-1 axis binding antagonists and taxanes
|
US20150190506A1
(en)
|
2013-12-17 |
2015-07-09 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
JP2017516458A
(en)
|
2014-03-24 |
2017-06-22 |
ジェネンテック, インコーポレイテッド |
Cancer treatment with c-met antagonist and correlation with HGF expression of c-met antagonist
|
CN106132439A
(en)
|
2014-03-31 |
2016-11-16 |
豪夫迈·罗氏有限公司 |
Comprise antiangiogenic agent and OX40 combines the combination treatment of agonist
|
BR112016022658A2
(en)
|
2014-03-31 |
2017-10-17 |
Genentech Inc |
anti-ox40 antibodies and methods of use
|
WO2016036873A1
(en)
|
2014-09-05 |
2016-03-10 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
EP3193866A1
(en)
|
2014-09-19 |
2017-07-26 |
Genentech, Inc. |
Use of cbp/ep300 and bet inhibitors for treatment of cancer
|
WO2016057924A1
(en)
|
2014-10-10 |
2016-04-14 |
Genentech, Inc. |
Pyrrolidine amide compounds as histone demethylase inhibitors
|
BR112017009151A2
(en)
|
2014-11-03 |
2018-03-06 |
Genentech, Inc. |
Assays for Detecting Immune T-Cell Subgroups and Methods of Using Them
|
SG11201703521UA
(en)
|
2014-11-03 |
2017-05-30 |
Genentech Inc |
Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
KR20170072343A
(en)
|
2014-11-06 |
2017-06-26 |
제넨테크, 인크. |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
JP6639497B2
(en)
|
2014-11-10 |
2020-02-05 |
ジェネンテック, インコーポレイテッド |
Bromodomain inhibitors and uses thereof
|
MA40940A
(en)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
SUBSTITUTED PYRROLOPYRIDINES USED AS BROMODOMA INHIBITORS
|
MA40943A
(en)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
SUBSTITUTED PYRROLOPYRIDINES USED AS BROMODOMA INHIBITORS
|
MX2017006320A
(en)
|
2014-11-17 |
2017-08-10 |
Genentech Inc |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists.
|
JP6771464B2
(en)
|
2014-11-27 |
2020-10-21 |
ジェネンテック, インコーポレイテッド |
4,5,6,7-Tetrahydro-1H-pyrazolo [4,3-C] Pyridine-3-amine compound as CBP and / or EP300 inhibitor
|
SG11201704707PA
(en)
|
2014-12-23 |
2017-07-28 |
Genentech Inc |
Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
|
CN107208138A
(en)
|
2014-12-30 |
2017-09-26 |
豪夫迈·罗氏有限公司 |
For cancer prognosis and the method and composition for the treatment of
|
WO2016112251A1
(en)
|
2015-01-09 |
2016-07-14 |
Genentech, Inc. |
4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors
|
CN107406414B
(en)
|
2015-01-09 |
2022-04-19 |
基因泰克公司 |
(piperidin-3-yl) (naphthalen-2-yl) methanone derivatives as inhibitors of histone demethylase KDM2B for the treatment of cancer
|
WO2016112298A1
(en)
|
2015-01-09 |
2016-07-14 |
Genentech, Inc. |
Pyridazinone derivatives and their use in the treatment of cancer
|
WO2016123391A1
(en)
|
2015-01-29 |
2016-08-04 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
EP3250552B1
(en)
|
2015-01-30 |
2019-03-27 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
MA41598A
(en)
|
2015-02-25 |
2018-01-02 |
Constellation Pharmaceuticals Inc |
PYRIDAZINE THERAPEUTIC COMPOUNDS AND THEIR USES
|
CN107709364A
(en)
|
2015-04-07 |
2018-02-16 |
豪夫迈·罗氏有限公司 |
Antigen binding complex and application method with agonist activity
|
CA2983282A1
(en)
|
2015-05-12 |
2016-11-17 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
ES2789500T5
(en)
|
2015-05-29 |
2023-09-20 |
Hoffmann La Roche |
Therapeutic and diagnostic procedures for cancer
|
WO2016200836A1
(en)
|
2015-06-08 |
2016-12-15 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies
|
MX2017015937A
(en)
|
2015-06-08 |
2018-12-11 |
Genentech Inc |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists.
|
WO2016205320A1
(en)
|
2015-06-17 |
2016-12-22 |
Genentech, Inc. |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
CA2996233C
(en)
|
2015-08-26 |
2024-01-16 |
Fundacion Del Sector Publico Estatal Centro Nacional De Investigaciones Oncologicas Carlos Iii (F.S.P. Cnio) |
Condensed tricyclic compounds as protein kinase inhibitors
|
KR20230125094A
(en)
|
2015-09-25 |
2023-08-28 |
제넨테크, 인크. |
Anti-tigit antibodies and methods of use
|
AU2016369528B2
(en)
|
2015-12-16 |
2021-04-22 |
Genentech, Inc. |
Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer
|
JP6949030B2
(en)
|
2016-01-08 |
2021-10-13 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Treatment of CEA-Positive Cancer Using PD-1 Axial Binding Antagonists and Anti-CEA / Anti-CD3 Bispecific Antibodies
|
KR20180119632A
(en)
|
2016-02-29 |
2018-11-02 |
제넨테크, 인크. |
Treatment and Diagnosis Methods for Cancer
|
US20170319688A1
(en)
|
2016-04-14 |
2017-11-09 |
Genentech, Inc. |
Anti-rspo3 antibodies and methods of use
|
JP2019518426A
(en)
|
2016-04-15 |
2019-07-04 |
ジェネンテック, インコーポレイテッド |
Cancer diagnosis and treatment method
|
MX2018012492A
(en)
|
2016-04-15 |
2019-06-06 |
Genentech Inc |
Methods for monitoring and treating cancer.
|
EP3443120A2
(en)
|
2016-04-15 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Methods for monitoring and treating cancer
|
CN115028617A
(en)
|
2016-05-24 |
2022-09-09 |
基因泰克公司 |
Heterocyclic inhibitors of CBP/EP300 and their use in the treatment of cancer
|
CN109476663B
(en)
|
2016-05-24 |
2021-11-09 |
基因泰克公司 |
Pyrazolopyridine derivatives for the treatment of cancer
|
US20200129519A1
(en)
|
2016-06-08 |
2020-04-30 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
WO2018027204A1
(en)
|
2016-08-05 |
2018-02-08 |
Genentech, Inc. |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
EP3497129A1
(en)
|
2016-08-08 |
2019-06-19 |
H. Hoffnabb-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
TWI775781B
(en)
|
2016-10-06 |
2022-09-01 |
美商建南德克公司 |
Therapeutic and diagnostic methods for cancer
|
JP2019535250A
(en)
|
2016-10-29 |
2019-12-12 |
ジェネンテック, インコーポレイテッド |
Anti-MIC antibody and method of use
|
KR20190134631A
(en)
|
2017-03-01 |
2019-12-04 |
제넨테크, 인크. |
How to diagnose and treat cancer
|
JP2020516638A
(en)
|
2017-04-13 |
2020-06-11 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Interleukin 2 immunoconjugates, CD40 agonists, and optional PD-1 axis binding antagonists for use in a method of treating cancer
|
EP3679159A1
(en)
|
2017-09-08 |
2020-07-15 |
H. Hoffnabb-La Roche Ag |
Diagnostic and therapeutic methods for cancer
|
US11369608B2
(en)
|
2017-10-27 |
2022-06-28 |
University Of Virginia Patent Foundation |
Compounds and methods for regulating, limiting, or inhibiting AVIL expression
|
EP3707510B1
(en)
|
2017-11-06 |
2024-06-26 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for cancer
|
AU2019275404A1
(en)
|
2018-05-21 |
2020-12-03 |
Bruker Spatial Biology, Inc. |
Molecular gene signatures and methods of using same
|
SG11202012446UA
(en)
|
2018-06-23 |
2021-01-28 |
Genentech Inc |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
MX2021000558A
(en)
|
2018-07-18 |
2021-04-13 |
Genentech Inc |
Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent.
|
TW202024023A
(en)
|
2018-09-03 |
2020-07-01 |
瑞士商赫孚孟拉羅股份公司 |
Therapeutic compounds and methods of use
|
MX2021003214A
(en)
|
2018-09-19 |
2021-05-12 |
Genentech Inc |
Therapeutic and diagnostic methods for bladder cancer.
|
MX2021003213A
(en)
|
2018-09-21 |
2021-05-12 |
Genentech Inc |
Diagnostic methods for triple-negative breast cancer.
|
EP3867646A1
(en)
|
2018-10-18 |
2021-08-25 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
WO2020163589A1
(en)
|
2019-02-08 |
2020-08-13 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
JP2022521773A
(en)
|
2019-02-27 |
2022-04-12 |
ジェネンテック, インコーポレイテッド |
Dosing for treatment with anti-TIGIT antibody and anti-CD20 antibody or anti-CD38 antibody
|
CA3131268A1
(en)
|
2019-02-27 |
2020-09-03 |
Epiaxis Therapeutics Pty Ltd |
Methods and agents for assessing t-cell function and predicting response to therapy
|
WO2020223233A1
(en)
|
2019-04-30 |
2020-11-05 |
Genentech, Inc. |
Prognostic and therapeutic methods for colorectal cancer
|
KR20220004744A
(en)
|
2019-05-03 |
2022-01-11 |
제넨테크, 인크. |
Methods of Treating Cancer Using Anti-PD-L1 Antibodies
|
CN112300279A
(en)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
Methods and compositions directed to anti-CD 73 antibodies and variants
|
MX2022002738A
(en)
|
2019-09-04 |
2022-06-27 |
Genentech Inc |
Cd8 binding agents and uses thereof.
|
EP4048693A1
(en)
|
2019-09-27 |
2022-08-31 |
F. Hoffmann-La Roche AG |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
CN114728936A
(en)
|
2019-10-29 |
2022-07-08 |
豪夫迈·罗氏有限公司 |
Bifunctional compounds for the treatment of cancer
|
MX2022005400A
(en)
|
2019-11-06 |
2022-05-24 |
Genentech Inc |
Diagnostic and therapeutic methods for treatment of hematologic cancers.
|
KR20220101138A
(en)
|
2019-11-13 |
2022-07-19 |
제넨테크, 인크. |
Therapeutic compounds and methods of use
|
US11845799B2
(en)
|
2019-12-13 |
2023-12-19 |
Genentech, Inc. |
Anti-Ly6G6D antibodies and methods of use
|
AU2020408562A1
(en)
|
2019-12-20 |
2022-06-23 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
IL294800A
(en)
|
2020-01-27 |
2022-09-01 |
Genentech Inc |
Methods for treatment of cancer with an anti-tigit antagonist antibody
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021177980A1
(en)
|
2020-03-06 |
2021-09-10 |
Genentech, Inc. |
Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
|
EP4127724A1
(en)
|
2020-04-03 |
2023-02-08 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
CN115885050A
(en)
|
2020-04-28 |
2023-03-31 |
基因泰克公司 |
Methods and compositions for non-small cell lung cancer immunotherapy
|
MX2022015877A
(en)
|
2020-06-16 |
2023-01-24 |
Genentech Inc |
Methods and compositions for treating triple-negative breast cancer.
|
US20210395366A1
(en)
|
2020-06-18 |
2021-12-23 |
Genentech, Inc. |
Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
EP4189121A1
(en)
|
2020-08-03 |
2023-06-07 |
Genentech, Inc. |
Diagnostic and therapeutic methods for lymphoma
|
EP4196612A1
(en)
|
2020-08-12 |
2023-06-21 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
AU2021347232A1
(en)
|
2020-09-23 |
2023-04-27 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
WO2022076462A1
(en)
|
2020-10-05 |
2022-04-14 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2022133345A1
(en)
|
2020-12-18 |
2022-06-23 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
WO2022171745A1
(en)
|
2021-02-12 |
2022-08-18 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives for the treatment of cancer
|
TW202313633A
(en)
|
2021-05-25 |
2023-04-01 |
美商伊瑞斯卡公司 |
Sulfur-containing heteroaromatic tricyclic kras inhibitors
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
TW202321261A
(en)
|
2021-08-10 |
2023-06-01 |
美商伊瑞斯卡公司 |
Selective kras inhibitors
|
TW202332429A
(en)
|
2021-11-24 |
2023-08-16 |
美商建南德克公司 |
Therapeutic compounds and methods of use
|
WO2023097194A2
(en)
|
2021-11-24 |
2023-06-01 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
TW202413433A
(en)
|
2022-07-19 |
2024-04-01 |
美商建南德克公司 |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024033458A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives
|
WO2024033388A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033389A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033457A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024085242A2
(en)
|
2022-10-21 |
2024-04-25 |
Kawasaki Institute Of Industrial Promotion |
Non-fouling or super stealth vesicle
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|